Leadership & Pay ·
Harmony Biosciences appoints Peter Anastasiou as CEO, replacing Jeffrey Dayno
HRMYHarmony Biosciences Holdings, Inc.
Harmony Biosciences announced a planned leadership transition effective January 1, 2027. Current Chief Operating Officer Peter Anastasiou has been appointed President and Chief Executive Officer, succeeding Jeffrey M. Dayno, who will retire from his executive role and step down as a Class I director on December 31, 2026. Dr. Dayno will serve as a non-executive advisor through 2027 to support the transition. The company reiterated its full-year 2026 WAKIX net revenue guidance of $1.0 billion to $1.04 billion and confirmed it remains on track to report data from the multiple ascending dose study of BP-205 in Q4 2026. Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases.